Douglas Galasko

2 ta ish

University of California San Diego

1. Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

   Ruth Motter, Carmen Vigo‐Pelfrey, Dora Kholodenko +14

   Maqola19952 iqtibos

   ABIABI:AkademIndex/2026.other.775789

2. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

   Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira +32

   Sharh maqola20242 iqtibos

   ABIABI:AkademIndex/2026.other.870812